The present application generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The application further provides materials and methods for application treatment of diseases involving aberrant B-cell activity. In addition, the application provides humanized CD37-specific binding molecules.
